BDF Gestion Lowers Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• BDF Gestion reduced its holdings in Thermo Fisher Scientific Inc. by 9.8% in the second quarter, now owning 12,308 shares valued at approximately $4.99 million.
• Several hedge funds, including Vanguard Group and Amundi, have increased their stakes in Thermo Fisher, highlighting strong institutional interest with over 89% of shares held by institutional investors.
• Analysts maintain a consensus target price of $588.35 for Thermo Fisher Scientific, with many reporting positive outlooks despite recent price cuts from firms like Wells Fargo and Evercore ISI.

BDF Gestion trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 12,308 shares of the medical research company's stock after selling 1,342 shares during the period. BDF Gestion's holdings in Thermo Fisher Scientific were worth $4,990,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $30,000. Finally, Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $31,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday, July 11th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Stock Down 0.6%

Shares of TMO traded down $3.04 during midday trading on Tuesday, reaching $471.95. The stock had a trading volume of 2,126,564 shares, compared to its average volume of 2,392,631. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company's fifty day simple moving average is $472.99 and its two-hundred day simple moving average is $448.55. The company has a market cap of $178.21 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.